Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

.S. generally accepted accounting principles

(GAAP). Please see the Form 8-K, furnished on November 1, 2007, by

the Company to the Securities and Exchange Commission for a discussion

of why the Company believes these non-GAAP measures are useful to

investors and the additional purposes for which management uses these

measures.

(2) The Company adopted Statement of Financial Accounting Standards No.

123R (SFAS 123R) as of January 1, 2006 and records stock-based

compensation expense in its statement of operations. Although this

expense is a significant ongoing expense affecting the Company's

results of operations, the Company excludes this charge from its non-

GAAP R&D, non-GAAP SG&A, non-GAAP net income and non-GAAP net income

per share because: (1) the Company's management excludes this expense

from the Company's budget and planning process used to allocate

resources in the Company's ongoing portfolio prioritization efforts,

(2) the Company believes that excluding this expense could be helpful

in comparing the Company's financial results to periods prior to

January 1, 2006 because stock-based compensation charges are excluded

in the various operating expense categories and (3) as a result of

varying available valuation methodologies, subjective assumptions and

the variety of award types, the Company believes that excluding stock-

based compensation may enable useful comparisons of the Company's

operating results to its competitors. Non-GAAP net income and other

non-GAAP financial measures disclosed by the Company should not be

considered in isolation or as a substitute for GAAP. (3) GAAP net loss for 2007 includes amortization of intangibles of

approximately $34 million, stock-based compensation expense of


'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... been named the 2009 Life Sciences Company of the ... presented by LifeSciences British Columbia to recognize a local ... of British Columbia,s life sciences industry. This award recognizes ...
... Calif., April 9 Cell Biosciences, a provider of ... the closing of a $10 million Series C financing ... Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, ... Group also participated in the financing."We are very happy ...
... April 9 Cepheid (Nasdaq: CPHD ) today ... first quarter ended March 31, 2009, on Thursday, April 23, ... a management presentation at 2 p.m. Pacific Time on Thursday, ... the live webcast, please visit Cepheid,s website at ...
Cached Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... process whereby the genetic information of DNA is ... which have numerous different functions in living organisms. ... during gene expression, by relating the genetic information ... manufacturing proteins. , By examining the different ... an organism at a given time, researchers can ...
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2
... dominant male and female to reduce their personal contribution to ... in Functional Ecology . , By removing the large ... cycle in this species a team from the University ... investment strategies of the dominant pair and the survival of ...
... Albert Einstein College of Medicine of Yeshiva ... as its twelfth Institutional Founding Member (IFM). A collaboration ... organizations, NYGC aims to transform medical research and clinical ... facilities in North America. "Einstein is pleased to ...
... directly lead to new ways of designing trials that would ... next few years and could change outcome for patients." ... 2013 will build on topics discussed in previous years and ... video here[ http://www.youtube.com/watch?v=X_anpC5WZPg ]: Breast cancer heterogeneity ...
Cached Biology News:Einstein joins the New York Genome Center as 12th institutional founding member 2IMPAKT -- Translational research breast cancer conference 2IMPAKT -- Translational research breast cancer conference 3
...
... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Biology Products: